Poor quality data is an issue in many research fields – all too often, results carried out in one organization cannot be replicated elsewhere, and it is not always clear why. In medical research, consequences include poor decision-making resulting in higher failure rates and longer drug development times. There is therefore an urgent need for simple, sustainable solutions to improve data quality, and that’s where the EQIPD project comes in. Their goal is to deliver simple recommendations to facilitate data quality without impacting innovation.
The EQIPD project aims to establish simple, sustainable solutions that facilitate improvements in data quality without impacting innovation and freedom of research.
The aim is to enable a smoother, faster and safer transition from preclinical to clinical testing and drug approval by establishing common guidelines to strengthen the robustness, rigor and validity of research data to ensure drug safety and for researchers to develop new neurological drugs for conditions such as Alzheimer’s disease.
The €9.5m EQIPD project will last 3 years, and unite more than 20 research groups from industry and academia from 8 different countries.
Psychogenics as the co-leader in the Work Package 4 (WP4), brings more than 18 years of stringent and robust preclinical testing expertise in a variety of animal models of CNS disorders.
The goal of WP4 is to validate the principles, strategies, and research models to improve robustness and data quality in preclinical research impacting neuroscience and safety. Working with other sites in the consortium, PsychoGenics will identify biological and experimental variations and working with other groups help develop harmonized guidelines to improve the reproducibility of preclinical data.
To learn more about the project and its goals, please visit: www.eqipd.org
Universities, research organizations, public bodies, non-profit groups:
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500m turnover):
The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (IMI) under grant agreement No 777364. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and from the European Federation of Pharmaceutical Industries and Associations (EFPIA).
This communication reflects the author’s view and that neither IMI or the European Union, EFPIA or any Associated Partners are responsible for any use that may be made of the information contained therein.